



Board Agenda Item #	III C: Action Item
Date:	April 29, 2021
To:	Magnolia Board of Directors
From:	Alfredo Rubalcava, CEO & Superintendent
Staff Lead:	Derya Hajmeirza, Director of Human Resources
RE:	Approval of COVID-19 Testing through PMH Laboratory, Inc. For Co-located Sites (MSA 2, MSA 3, MSA 4, MSA 5, MSA 8)

Information Item:

I move that the board approve partnership with PMH Laboratory, Inc (“PMH”) of baseline, regular, symptomatic, and response testing for Magnolia Science Academy 2, 3, 4, 5, and 8 for the remainder of 2020-21 FY.

Introduction

Based on the board resolution adopted on July 23, 2020, the Board of Directors directed the following:

- The CEO is authorized to develop and implement a plan for reopening schools (the “Plan”) in Fall 2020 in accordance with guidance and/or directives from the chartering authority, and local, state or federal government officials, including, but not limited to, Relevant Authorities.
- The CEO or designee may hire additional employees or independent contractors as necessary or convenient for purposes of performing tasks recommended by Relevant Authorities or that the CEO deems necessary in their discretion to mitigate the actual or potential impacts of COVID-19.

Background

The above mentioned schools entered into an agreement with the Los Angeles Unified School District (LAUSD) for baseline and regular weekly testing for 2020-21 and 2021-22. However, in order for MPS to best serve their students, staff, and families, MPS wants to add an additional testing vendor for if and when needed where the LAUSD is unable to provide testing in a timely or efficient manner.

MPS is currently working with PMH for baseline and regular testing (as required) of staff and students at MSA 1, 6, 7, Santa Ana and San Diego. Additionally, as approved by the MPS board, PMH provided baseline testing for MSA 2 and MSA 5 on April 22, 2021 to safely and successfully get students back on campus on April 27th and 29th.

Budget Implications

Through the CARES Act, PMH covers all testing kits for all patients. MPS will be responsible for the cost of testing for patients who cannot show proof of insurance or SSN. This cost is expected to be minimal, if any.

Legal Review:

The PMH agreement has been reviewed by the MPS general counsel.

Exhibits (attachments):

N/A